CPRC
DXCM icon

Consolidated Portfolio Review Corp’s DexCom DXCM Stock Holding History

Consolidated Portfolio Review Corp’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,818
Closed -$246K – 462
2025
Q2 		$246K Buy
+2,818
New +$221K 0.03% 390
2025
Q1 		– Sell
-2,824
Closed -$220K – 383
2024
Q4 		$220K Buy
+2,824
New +$209K 0.03% 341
2024
Q3 		– Sell
-2,824
Closed -$320K – 315
2024
Q2 		$320K Buy
2,824
+11
+0.4% +$1.39K 0.07% 228
2024
Q1 		$390K Buy
2,813
+205
+8% +$25.8K 0.1% 180
2023
Q4 		$324K Sell
2,608
-29
-1% -$2.96K 0.07% 222
2023
Q3 		$246K Buy
2,637
+29
+1% +$3.27K 0.06% 269
2023
Q2 		$335K Hold
2,608
– – 0.08% 216
2023
Q1 		$303K Buy
+2,608
New +$292K 0.08% 208

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Consolidated Portfolio Review Corp's DXCM Position: Q3 2025 in Review

Consolidated Portfolio Review Corp sold out of DexCom (DXCM) in Q3 2025, closing a stake of 2,818 shares — an estimated $246K sold.

Consolidated Portfolio Review Corp first reported a position in DXCM in Q1 2023 and held it in 8 quarters. The position peaked at $390K in Q1 2024. 911 funds tracked by Wall St. Rank hold DXCM as of Q3 2025.

  • Consolidated Portfolio Review Corp reported no remaining DexCom position as of Q3 2025 after selling out during the quarter.
  • Consolidated Portfolio Review Corp sold 2,818 DexCom shares in Q3 2025, an estimated $246K.
  • Consolidated Portfolio Review Corp first reported a position in DexCom in Q1 2023 and held it in 8 quarters.
  • Consolidated Portfolio Review Corp's DexCom position peaked at $390K in Q1 2024.
  • 911 funds tracked by Wall St. Rank held DexCom as of Q3 2025.

Based on Consolidated Portfolio Review Corp's 13F filing for Q3 2025, filed 12 Nov 2025.